Where Equipment and System Meet | Global Health Infrastructure Index

The previous case study laid out an argument that access to care is a healthcare system problem, not an infrastructure problem. This one extends that argument and tests it against an operational example: where, in practice, does infrastructure investment actually deliver full effectiveness? The answer is narrow — it requires both the system and the financing to come together at the same time. Pakistan's Shaukat Khanum cancer hospital is the clearest case I encountered of that working.

I sat down earlier this year with a cardiac electrophysiologist who serves on the board of an international medical relief organization. His full-time practice is in the United States, but he travels internationally to perform procedures — pacemaker implants, ablations, complex rhythm cases — including a recent mission to Colombia. The same procedure costs an order of magnitude less abroad. And yet, in many of the settings he discussed, patients still cannot get the care they need.

His observations reinforced the previous case study's central point — access is a system problem — and pushed it further. Even when a visiting physician brings the equipment, performs the procedure, and donates the time, the surrounding system still decides who walks through the door. The bottleneck is rarely the device.

The economics of bringing equipment

For most international cardiac procedures, the visiting physician brings the equipment with them. Catheters. Pacemakers. Specialty supplies that local hospitals don't reliably stock or can't afford. A pacemaker that costs $5,000 to $25,000 in the United States — typically negotiated directly between the hospital and the manufacturer, and covered by insurance — is procured through a different channel abroad. Outside the US, hospitals usually buy through third-party distributors, who add margin and friction.

A one-week procedural mission to Colombia runs roughly $25,000 in non-clinical costs alone — funded through individual donations. That covers medications, translators, logistics, supplies. None of it is the procedure. All of it has to clear before the procedure can happen.

$25kCost of a 1-week mission to Colombia (non-clinical)
$5–25kUS pacemaker price; lower abroad but distributor-mediated
8 yrsTypical pacemaker replacement interval

An Ecuador mission was cancelled the same year because of a dengue outbreak. The country didn't disappear; the access window did. This is what variable risk looks like in practice — every trip absorbs the upfront cost regardless of whether it actually delivers care.

Lebanon — when bringing the equipment isn't enough

The most pointed example came from Lebanon. In a country whose health system has collapsed alongside its currency, hospitals require upfront payment in cash before they will admit a patient — even when the visiting physician is bringing the device for free, and even when the patient is in a refugee setting where cash pooling among extended family is the only viable funding mechanism.

The math is brutal. The procedure cost is sunk. The equipment cost is sunk. The physician's time is donated. And yet a third party — the hospital's admission desk — still gates access on a payment that the patient may not be able to assemble.

One implication he raised was striking: it might be cheaper, and more useful, to bring cash than to bring equipment. Cash supports the local economy and clears the admission gate. Equipment shipped from abroad is more visible as a contribution and more comfortable for donors, but in markets where hospitals don't negotiate directly with manufacturers — and instead procure through layers of third-party distributors who add their own margin — a meaningful share of the donated value disappears into the supply chain before it reaches a patient.

Equipment that cannot enter the system because the patient cannot enter the hospital is, functionally, equipment that does not exist. This is what a "Yellow" or "Red" policy environment looks like at the level of an individual procedure.

Pakistan — what happens when the device wears out

A patient with cardiomyopathy in Pakistan received a life-saving pacemaker through one of his missions. The implant went well. Eight years later — within the normal service life of the device — the pacemaker needed replacement. The hospital directed the patient to a distributor to obtain the new device. The patient could not afford it. The replacement was eventually funded through a combination of charitable donations and a GoFundMe campaign.

Note what's happening here. The clinical knowledge exists. The hospital exists. The patient is alive and in care. The original implant was successful. And yet, eight years on, the system has no answer for a routine, predictable, eight-year-cadence event other than asking the patient to crowdfund their own care. The infrastructure visible in this story isn't medical — it's financial plumbing, and it's missing.

This is the same insight Iraq's imaging supplier surfaced from the equipment-procurement side: in markets where insurance, financing, and direct manufacturer relationships are absent, distributor-mediated transactions become the default — and the patient ends up bearing risks the system cannot absorb.

Cambodia — the high-efficiency low-resource model

The flip side of these examples is what happens when a system is forced to operate with extreme resource constraints. In Cambodia, he described a cardiac care model built around relentless reuse and family-supported care delivery.

Equipment that would be single-use disposable in the US is sterilized and reused. Even basic supplies — gauze, drapes — get washed and reused. Ablations use reusable sheath systems. Patient throughput is high because the marginal cost per case is kept low. Families fill in around the edges of formal care: feeding, cleaning, basic patient support.

It would be easy to read this as a story about hardship. The more useful read is that it's a story about what efficiency actually looks like when the disposable supply economy isn't available to absorb costs invisibly. The US cardiac care model, by contrast, is built around dense disposable use — a luxury enabled by insurance reimbursement that most systems cannot replicate. There are practices in the Cambodia model that high-resource systems would benefit from studying. Most of them won't, because they don't have to.

Pakistan — the operational proof point

The most important example in the conversation came from a different part of Pakistan. Shaukat Khanum Memorial Cancer Hospital — founded by Imran Khan after his mother died from cancer — was widely seen as infeasible at launch. The premise was hard to defend on paper: deliver high-quality cancer care, free at the point of service, in a country whose per-capita health spending and public infrastructure should not have been able to support it. The first hospital opened in Lahore in 1994. A second opened in Peshawar in 2015. A third is under construction in Karachi, scheduled to open in 2026. Today the network funds free or partially-free treatment for the majority of its patients with limited means, supported through a global donor base.

This is the operational example that ties this case study to the previous one. The previous case study argued that access is a healthcare system problem rather than an infrastructure problem. Shaukat Khanum is what it looks like when someone solves both at once, in a country where the surrounding system was supposed to make it impossible.

What the hospital got right is exactly what Lebanon's admission desk and Pakistan's pacemaker-replacement story illustrate by their absence: access and financing have to be solved at the same time. The hospital invested in significant capital equipment — large-scale imaging, monitoring infrastructure, treatment capacity. It built clinical sophistication. And it built — separately and explicitly — the financing model that allowed patients to walk through the door without producing cash up front.

Either alone would have failed. Equipment without a financing model would have produced an empty waiting room, like Lebanon's admission desk illustrates. A financing model without clinical capacity would have produced no care to fund. The combination — built deliberately, in the same institution, at the same time — is what makes the Shaukat Khanum model durable enough to deliver world-class oncology care in a country whose national health indicators predict otherwise.

Shaukat Khanum is the answer to the question "what does full effectiveness look like in a low-capital environment with a fragmented surrounding system?" It looks like a single institution that intentionally built its own integrated system inside the country's broader one — equipment and financing together, neither one without the other.

What this means for the framework

Three observations from this case study connect directly to the framework's three axes.

Capital allocation, in practice, is mediated by distributors and admission desks. When measuring "capital reaching the system," the question is not just how much money exists. It's whether the money clears every gate between the donor and the patient. Distributor margins, upfront payment requirements, missing insurance coverage — these all reduce the effective capital reaching care, even when the headline number looks higher.

Policy alignment is what determines whether brought-in equipment gets used. A red-policy environment can absorb donated equipment without delivering proportional care, because the gates the equipment has to clear (admission policies, regulatory paperwork, distributor mediation) aren't aligned with patient outcomes. A yellow-policy environment lets some donations through and stalls others. A green-policy environment converts donations efficiently into care delivered.

Sophistication tier shapes the form of effective intervention. A foundational-tier intervention sends primary-care physicians and basic supplies. An advanced-tier intervention sends specialists and complex devices. Mismatching the tier to the system — sending pacemakers to a system that can't replace them in eight years — produces stories like the Pakistan cardiomyopathy patient: a single moment of care followed by a structural inability to continue it.

The takeaway

The previous case study argued that access is a healthcare system problem, not an infrastructure problem. This one shows what that argument looks like at the level of an individual procedure, an individual hospital, and an individual country. Equipment can absolutely be a constraint — the right device is sometimes precisely what is missing. But equipment in isolation runs into a ceiling that more equipment cannot break through. The most leveraged interventions in markets like Lebanon and Pakistan are the ones that put equipment and the surrounding system to work in unison: clinical capacity paired with financing, devices paired with admission policies that let patients reach them, donations paired with the supply chains that can sustain replacements eight years later. Shaukat Khanum is the encouraging proof that this unity can be deliberately built — even in countries whose surface-level health systems do not have the proper incentive structures to support it. The question for any allocator working in a low-capital country is whether the specific intervention they're funding is set up for that kind of unity, or whether it is one half of a solution looking for the other.